Astellas Pharma vs. Lupin: Xtandi® Patent Infringement Claims Dismissed With Prejudice
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Lupin Limited |
| Case Number | 3:25-cv-13779 |
| Court | U.S. District Court for the District of New Jersey |
| Duration | July 25, 2025 – Feb 9, 2026 199 days (~6.5 months) |
| Outcome | Plaintiff Claims Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Xtandi® tablets (40 mg and 80 mg) as per Lupin’s ANDA filing |
Case Overview
The Parties
⚖️ Plaintiff
Global biopharmaceutical company headquartered in Tokyo, Japan, with major U.S. operations. Xtandi® (enzalutamide) is among its flagship oncology products, approved by the FDA for prostate cancer.
🛡️ Defendant
One of India’s largest pharmaceutical manufacturers with a significant U.S. generics presence, routinely filing Abbreviated New Drug Applications (ANDAs) challenging branded drug patents.
The Patents at Issue
This landmark case involved two U.S. patents asserted against Lupin’s ANDA filing, protecting aspects of the blockbuster prostate cancer treatment Xtandi® (enzalutamide). Both patents relate to formulations or methods associated with **Xtandi® tablets (40 mg and 80 mg)**, protecting aspects of the enzalutamide product line. Specific claim language was not disclosed in publicly available case data; however, late-stage Xtandi® patents typically address formulation improvements, dosing methods, or manufacturing processes rather than the core active compound. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US 11,839,689 B2 — Related to formulations or methods of Xtandi® tablets
- • US 12,161,628 B2 — Related to formulations or methods of Xtandi® tablets
Developing a similar pharmaceutical product?
Check if your drug formulation or method of use might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered a Dismissal Order, specifying that “each plaintiff’s claims against Lupin with respect to patents-in-suit is dismissed with prejudice.” The dismissal with prejudice is the operative legal mechanism — it extinguishes Astellas’s right to re-litigate these specific infringement claims on these patents against Lupin. No damages award or injunctive relief was recorded in the case data. Specific financial terms of any underlying agreement were not disclosed.
Verdict Cause Analysis
The case was initiated as a standard infringement action, consistent with Hatch-Waxman 30-month stay litigation mechanics. Under the Hatch-Waxman Act, a branded drug company has 45 days from receiving an ANDA Paragraph IV certification to file suit and trigger an automatic 30-month stay on FDA approval of the generic product. Astellas’s filing on July 25, 2025, follows this established pattern.
The dismissal with prejudice — as opposed to a court-ordered ruling on validity or infringement — means no substantive legal findings were made on:
- • Whether claims of U.S. Patents 11,839,689 or 12,161,628 were valid
- • Whether Lupin’s proposed generic product would infringe those claims
- • Claim construction of any disputed patent terms
This outcome is legally neutral on the merits. It does not establish that Lupin’s ANDA product infringes or does not infringe, nor does it speak to patent validity. The patents remain in force.
Legal Significance
For Hatch-Waxman litigation practitioners, this pattern — expedited resolution and prejudicial dismissal — is increasingly common as pharmaceutical parties negotiate commercial arrangements outside judicial resolution. The case reinforces that New Jersey District Court remains a preferred venue for these disputes, and that parties frequently resolve ANDA litigation before substantive milestones like Markman hearings.
The involvement of two continuation-style patents (based on related application numbers 17/985,235 and 17/959,350) illustrates Astellas’s layered patent prosecution strategy for Xtandi® — filing multiple related applications to maintain overlapping protection as earlier patents approach expiration. This evergreening approach is both legally defensible and strategically significant.
Strategic Takeaways
For Patent Holders:
- • Maintaining a continuation patent family provides negotiating leverage even where core compound patents have expired or face validity risk.
- • Early-stage dismissal may reflect favorable licensing terms rather than weakness — preserve optionality through strong prosecution.
For Accused Infringers (Generic Manufacturers):
- • Dismissal with prejudice on negotiated terms may secure a defined generic entry date, providing commercial certainty.
- • New Jersey venue requires experienced local counsel with deep Hatch-Waxman litigation knowledge.
For R&D & Regulatory Teams:
- • Freedom-to-operate (FTO) analysis must account for continuation patent families, not merely lead patents, especially in pharmaceutical formulation spaces.
- • ANDA filers should assess whether post-grant proceedings (IPR, PGR) at the USPTO offer a cost-effective alternative or parallel challenge track.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for pharmaceutical IP.
- View all related patents for Xtandi®
- See which companies are most active in oncology IP
- Understand pharmaceutical claim construction trends
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or method of use.
- Input your drug description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Enzalutamide formulations/methods
2 Patents at Issue
Specific to Xtandi®
Strategic Dismissal
Indicates negotiated settlement
✅ Key Takeaways
Dismissal with prejudice signals commercial resolution, not a merits ruling — patents 11,839,689 and 12,161,628 remain enforceable.
Search related case law →New Jersey District Court’s efficiency in pharmaceutical patent cases continues to make it the preferred Hatch-Waxman venue.
Explore precedents →Continuation patent families remain powerful litigation and licensing leverage tools in pharmaceutical portfolios.
Analyze patent families →The 199-day resolution underscores that pre-Markman settlement is a viable and frequently pursued outcome.
Review settlement trends →Frequently Asked Questions
The case involved U.S. Patent Nos. 11,839,689 B2 and 12,161,628 B2, both related to Xtandi® (enzalutamide) tablets in 40 mg and 80 mg formulations.
The court entered a dismissal with prejudice of all plaintiff’s claims. The case data does not specify whether dismissal followed a negotiated settlement; no findings on infringement or validity were made.
The dismissal does not establish precedent on claim construction or validity. Parallel ANDA litigation cases involving other generic filers may produce substantive rulings with broader implications for Xtandi®’s patent estate.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Locator
- USPTO Patent Center – US11839689B2
- Hatch-Waxman Litigation Overview – FDA
- Cornell Legal Information Institute — 35 U.S.C. § 289
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.